Clinical Information Search
Search Results for "diabetes_articles"
- Online Learning Center (0)
- Policy Library (103)
- Performance Measures (0)
- Annals of Internal Medicine (1952)
- Annals of Internal Medicine: Clinical Cases (143)
- IM Matters (6)
- ACP Hospitalist (42)
- ACP Diabetes Monthly (58)
- ACP Gastroenterology Monthly (4)
Sorry, no results were found for "diabetes_articles" in Online Learning Center.
Sorry, no results were found for "diabetes_articles" in Performance Measures.
Displaying 221 - 230 of 1952 in Annals of Internal Medicine
These Annals of Internal Medicine results only contain recent articles.
- Visit annals.org to search all content back to 1927.
- View Annals of Internal Medicine CME by topic here.
In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders
Source Citation Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989. 33567185
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
Source Citation Palmer SC, Tendal B, Mustafa RA, et al. Sodium–glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. 33441402
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
Source Citation Douros A, Lix LM, Fralick M, et al. Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020;173:417-25. 32716707
In older adults with type 1 diabetes, continuous glucose monitoring reduced hypoglycemia over 6 months
Source Citation Pratley RE, Kanapka LG, Rickels MR, et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323:2397-406. 32543682
In type 2 diabetes, some glucose-lowering drugs reduce HbA1c more than others; drugs do not differ for mortality
Source Citation Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020;173:278-86. 32598218
In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA1c and SBP and may reduce body weight
Source Citation Mantsiou C, Karagiannis T, Kakotrichi P, et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2020;22:1857-68. 32476254
SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
Source Citation Liu J, Li L, Li S, et al. Sodium–glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22:1619-27. 32364674
In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years
Source Citation Griffin SJ, Rutten GEHM, Khunti K, et al. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7:925-37. 31748169
In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach
Source Citation Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394:1519-29. 31542292
In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
Source Citation Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845-54. 31495651